[TOPIC] – Complete Pathology (NEET PG 2026) Definition
[Insert precise exam-ready definition of TOPIC here, including whether it is inherited/acquired, benign/malignant, acute/chronic, and hallmark pathology.]

Genetic/Molecular Basis
Key genes/chromosomes: [Gene 1], [Gene 2], [Translocation/Mutation]
Molecular mechanism: [Driver pathway/receptor/enzyme abnormality] leading to [cellular effect].
Inheritance/Acquisition: [AD/AR/X-linked/sporadic/somatic clonal].
High-yield marker: [Most tested molecular/immunophenotypic marker].

Pathophysiology (Step by Step)
1. Initiating event: [Primary trigger: mutation/infection/autoimmunity/toxin/hemodynamic change].
2. Cellular response: [Inflammation/proliferation/apoptosis failure/dysplasia].
3. Tissue-level change: [Edema/fibrosis/necrosis/hyperplasia/metaplasia].
4. Vascular/immune impact: [Cytokines/complement/coagulation/microthrombi].
5. Organ dysfunction: [How structure change causes symptoms/signs].
6. Complications: [Failure, rupture, transformation, thrombosis, etc.].

Organ Pathology
Gross: [Size, color, consistency, nodularity, infarction/hemorrhage pattern].
Microscopy: [Hallmark histology pattern], [cell type], [inclusions/bodies], [stroma changes].
Special stains/IHC: [PAS/Prussian blue/Congo red/reticulin/IHC markers] with expected finding.

Clinical Features
Symptoms: [Most common presenting complaints in order of frequency].
Signs: [Exam findings, organomegaly, lymphadenopathy, skin/mucosal signs].
Red flags: [Emergency signs/poor prognostic indicators].

Laboratory Findings
CBC: [Hb], [TLC], [platelets] typical trend.
Biochemistry: [LDH, bilirubin, uric acid, CRP/ESR, organ-specific markers].
Coagulation/hemolysis profile: [PT/aPTT/fibrinogen/D-dimer/haptoglobin/retic count as relevant].
Confirmatory tests: [Flow cytometry/cytogenetics/PCR/ELISA/biopsy findings].

Peripheral Smear
Characteristic cells: [Cell morphology: e.g., blasts, spherocytes, schistocytes, target cells, sickle cells].
RBC changes: [Anisopoikilocytosis/polychromasia/inclusions].
WBC changes: [Left shift/blasts/toxic granules].
Platelet changes: [Giant platelets/thrombocytopenia/clumping].
Most testable smear clue: [Single highest-yield morphology point].

Diagnosis
Diagnostic criteria: [Gold standard criteria/classification threshold].
Initial workup: [Stepwise approach from screening to confirmation].
Gold standard: [Biopsy/genetic test/imaging-lab combination].
Severity/Risk stratification: [Score/staging system and key cutoffs].

Differential Diagnoses
1. [DDx 1] – Distinguishing point: [How to separate from TOPIC].
2. [DDx 2] – Distinguishing point: [Lab/pathology discriminator].
3. [DDx 3] – Distinguishing point: [Clinical clue].
4. [DDx 4] – Distinguishing point: [Molecular/histology clue].

Management
Stabilization first: [Airway/breathing/circulation, transfusion, urgent measures if indicated].
Definitive therapy: [Drug class/procedure/surgery/transplant with first-line choice].
Targeted therapy: [If molecular target exists, mention prototype drug].
Supportive care: [Fluids, infection prophylaxis, folate, anticoagulation, etc.].
Monitoring: [Response markers, MRD/biomarker trends, complication surveillance].
Prognosis: [Best/worst prognostic factors and survival clue].

Exam Pearls (NEET PG Focus)
Most commonly asked association: [Classic association].
Most specific test: [High-specificity investigation].
Most sensitive early clue: [Earliest detectable finding].
Buzzwords: [buzzword 1], [buzzword 2], [buzzword 3].
Common trap: [Frequently confused entity and how to avoid error].

NEET PG One-Liners
• [TOPIC] is most strongly associated with [single best association].
• Gold standard for diagnosis is [test].
• Pathognomonic feature: [feature].
• Peripheral smear shows [hallmark cell].
• First-line treatment is [therapy].
• Poor prognostic marker: [marker].
• Must-not-miss differential: [condition].